Market revenue in 2020 | USD 4,220.7 million |
Market revenue in 2028 | USD 7,206.4 million |
Growth rate | 6.9% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | Neurodegenerative Diseases |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 46.84% in 2020. Horizon Databook has segmented the Italy central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
Disorders such as depression, schizophrenia, and neurosis are the most prevalent mental health disorders in Italy. On the other hand, the country also reports a high prevalence of dementia, most commonly due to Alzheimer’s disease, which has a prevalence of ~1%.
The Italian government’s project known as Interceptor helps in identifying individuals in the population with increased risk of developing the disease, with the aim of providing them early treatment. Such initiatives undertaken by the government are likely to increase the demand for neurodegenerative drugs over the forecast period.
Moreover, Parkinson’s, which currently has a 1% prevalence in population over 65 years of age, is likely to increase to with the rapidly aging population of Italy, driving the need for neurodegenerative drugs in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into Italy central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account